DK1096936T3 - Behandling af dyskinesi ved hjælp af mu selektive opioid antagonister - Google Patents

Behandling af dyskinesi ved hjælp af mu selektive opioid antagonister

Info

Publication number
DK1096936T3
DK1096936T3 DK99932991T DK99932991T DK1096936T3 DK 1096936 T3 DK1096936 T3 DK 1096936T3 DK 99932991 T DK99932991 T DK 99932991T DK 99932991 T DK99932991 T DK 99932991T DK 1096936 T3 DK1096936 T3 DK 1096936T3
Authority
DK
Denmark
Prior art keywords
dyskinesia
treatment
opioid antagonists
selective opioid
opioid receptor
Prior art date
Application number
DK99932991T
Other languages
Danish (da)
English (en)
Inventor
Jonathan Brotchie
Original Assignee
Motac Neuroscience Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Motac Neuroscience Ltd filed Critical Motac Neuroscience Ltd
Application granted granted Critical
Publication of DK1096936T3 publication Critical patent/DK1096936T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Mechanical Treatment Of Semiconductor (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Resistance Heating (AREA)
DK99932991T 1998-07-18 1999-07-16 Behandling af dyskinesi ved hjælp af mu selektive opioid antagonister DK1096936T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9815618.5A GB9815618D0 (en) 1998-07-18 1998-07-18 Treatment of dyskinesia
PCT/GB1999/002146 WO2000003715A1 (en) 1998-07-18 1999-07-16 Treatment of dyskinesia

Publications (1)

Publication Number Publication Date
DK1096936T3 true DK1096936T3 (da) 2007-07-30

Family

ID=10835727

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99932991T DK1096936T3 (da) 1998-07-18 1999-07-16 Behandling af dyskinesi ved hjælp af mu selektive opioid antagonister

Country Status (13)

Country Link
US (5) US6455536B1 (de)
EP (2) EP1792617A1 (de)
JP (2) JP2002520362A (de)
AT (1) ATE357917T1 (de)
AU (1) AU759342B2 (de)
CA (1) CA2338066C (de)
CY (1) CY1108054T1 (de)
DE (1) DE69935670T2 (de)
DK (1) DK1096936T3 (de)
ES (1) ES2285845T3 (de)
GB (1) GB9815618D0 (de)
PT (1) PT1096936E (de)
WO (1) WO2000003715A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9815618D0 (en) * 1998-07-18 1998-09-16 Univ Manchester Treatment of dyskinesia
GB9924941D0 (en) * 1999-10-22 1999-12-22 Univ Manchester Treatment of dyskinesia
GB0007193D0 (en) * 2000-03-25 2000-05-17 Univ Manchester Treatment of movrmrnt disorders
DE10041479A1 (de) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923
GB0027020D0 (en) * 2000-11-03 2000-12-20 Univ Manchester Treatment of movement disorders
US20060177381A1 (en) * 2002-02-15 2006-08-10 Howard Brooks-Korn Opiopathies
DE10361258A1 (de) 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson
DE102004014841B4 (de) 2004-03-24 2006-07-06 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms
CN101065014A (zh) * 2004-09-23 2007-10-31 亚历山大·米哈洛 通过诱导逆适应调节神经递质系统的方法
US20080045610A1 (en) * 2004-09-23 2008-02-21 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
JP2006131545A (ja) * 2004-11-05 2006-05-25 Japan Science & Technology Agency 神経因性疼痛治療剤
CN101686977B (zh) * 2007-04-24 2012-09-05 东丽株式会社 运动障碍的治疗或预防剂
WO2009126931A2 (en) 2008-04-11 2009-10-15 Xvasive, Inc. Combination therapy for bipolar disorder
US20100168119A1 (en) 2008-11-05 2010-07-01 Pharmorx, Inc. Compositions and methods for minimizing or reducing agonist-induced desensitization
US9918980B2 (en) 2011-04-29 2018-03-20 Rutgers, The State University Of New Jersey Method of treating dyskinesia
US10736889B2 (en) 2011-04-29 2020-08-11 Rutgers, The State University Of New Jersey Method of treating dyskinesia
EP2950799B1 (de) 2013-01-30 2019-12-04 Pharmorx Therapeutics, Inc. Behandlungen für depression und andere erkrankungen mit einem niedrigdosierten wirkstoff
EP3436013A4 (de) * 2016-03-31 2019-11-13 Versi Group, LLC Delta-opioid-agonist, mu-opioid-antagonist-zusammensetzungen und verfahren zur behandlung von morbus parkinson

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4390699A (en) * 1981-07-16 1983-06-28 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services 6-Keto-morphinans belonging to the 14-hydroxy-series
US4684620A (en) * 1984-09-04 1987-08-04 Gibson-Stephens Neuropharmaceuticals, Inc. Cyclic polypeptides having mu-receptor specificity
AR245933A1 (es) * 1987-04-16 1994-03-30 Lilly Co Eli Procedimiento para preparar compuestos de 4-(3-hidroxifenil)metil-3-alquil-n-alquilpiperidina y sus sales.
DE69231274T2 (de) * 1991-02-25 2000-11-30 Univ Boston Hyperkinetische bewegungsstörung modulierender opiatrezeptor-antagonist
JPH08512129A (ja) * 1993-06-23 1996-12-17 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 抗常習性麻酔鎮痛活性スクリーニングのための組成物および方法並びに治療
US5473620A (en) 1993-09-21 1995-12-05 Cirrus Logic, Inc. Programmable redundancy/syndrome generator
US5464841A (en) * 1993-11-08 1995-11-07 Univ Minnesota Use of delta opioid receptor antagonists to treat immunoregulatory disorders
US5597309A (en) * 1994-03-28 1997-01-28 Riess; Thomas Method and apparatus for treatment of gait problems associated with parkinson's disease
US5496836A (en) * 1994-05-05 1996-03-05 Mount Sinai School Of Medicine Of The City University Of New York Use of famotidine and related compounds in the treatment of movement disorders
US5821219A (en) * 1995-08-11 1998-10-13 Oregon Health Sciences University Opioid antagonists and methods of their use
GB9815618D0 (en) * 1998-07-18 1998-09-16 Univ Manchester Treatment of dyskinesia

Also Published As

Publication number Publication date
US20050009856A1 (en) 2005-01-13
JP2002520362A (ja) 2002-07-09
AU4918099A (en) 2000-02-07
US6455536B1 (en) 2002-09-24
DE69935670D1 (de) 2007-05-10
US8198294B2 (en) 2012-06-12
US20020137669A1 (en) 2002-09-26
US6740659B2 (en) 2004-05-25
CY1108054T1 (el) 2013-09-04
DE69935670T2 (de) 2008-01-31
ES2285845T3 (es) 2007-11-16
JP2011037877A (ja) 2011-02-24
EP1096936B1 (de) 2007-03-28
US20030060478A1 (en) 2003-03-27
US20100184797A1 (en) 2010-07-22
EP1096936A1 (de) 2001-05-09
WO2000003715A1 (en) 2000-01-27
AU759342B2 (en) 2003-04-10
ATE357917T1 (de) 2007-04-15
PT1096936E (pt) 2007-05-31
CA2338066A1 (en) 2000-01-27
CA2338066C (en) 2009-01-27
EP1792617A1 (de) 2007-06-06
GB9815618D0 (en) 1998-09-16

Similar Documents

Publication Publication Date Title
DK1096936T3 (da) Behandling af dyskinesi ved hjælp af mu selektive opioid antagonister
AU4926301A (en) Lpa receptor agonists and antagonists and methods of use
ATE424403T1 (de) Polycycloalkylpurine als adenosinrezeptorantagonisten
IL161074A0 (en) Lactam derivatives as antagonists for human 11cby receptors
FI971489A (fi) Uusia bentsoksatsoleja
CY1106560T1 (el) Ανταγωνιστες υποδοχεα αδενοσινης και μεθοδοι κατασκευης και χρησης αυτων
WO2005021496A3 (en) Synthesis of derivatives of ginkgolide c
NO985518L (no) Morfinanderivater og medisinsk anvendelse derav
NO20020574D0 (no) Substituerte 1,5-dihydropyrrol-2-onderivater som er virksomme som NMDA-reseptorantagonister for behandlingen av smertetilstanden
DK1200073T3 (da) Selektive iGluR5-receptorantagonister til behandling af migræne
NO20015259L (no) Substituerte bisykliske heterosykler, fremgangsmåte for deres fremstilling og deres anvendelse som antifedme oghyperkolesterolemiske midler
MXPA03007903A (es) Sistema terapeutico transdermico altamente flexible con nicotina como ingrediente activo.
DK1223930T3 (da) Behandling af dyskinesi
DE69718146T2 (de) At1 rezeptor antagonist zur anregung von apoptosis
NO20002408L (no) 5-HT1F antagonister
DK1224181T3 (da) Substituerede pyrroler som antiproliferative midler til behandling af cancer
DK1339398T3 (da) Behandling af motoriske fluktuationer med 5-hydroxytryptamin 1A receptoraktivitetsforstærkende forbindelser
BR0007395B1 (pt) compostos de s-nitrosotióis como agentes para o tratamento de disfunções circulatórias.
BR0210678A (pt) Carbamatos de 2-heterocìclicos-1,2-etanodióis
WO2002007766A3 (en) Use of d5-dopamine receptor agonists in the manufacture of a medicament for the treatment of dyskinesia
ES1042338Y (es) Barandilla de seguridad para trabajos en la construccion.
ZA200400824B (en) Pyridin-2-yl-methlyamine derivatives for treating opioid dependence.
WO2004067093A3 (en) Nk1 receptor antagonists for the treatment of functional dyspepsia
IT1307108B1 (it) Macchina palissonatrice per pelli.
DK1192156T3 (da) Bispidinforbindelser, som er egnede til behandling af hjertearytmier